General Surgery

Breast Cancer Surgery

Across 202,934 women with the same early disease, the proportion who kept the breast ran from 58.5 to 75.5 percent depending on the region. Breast cancer surgery is not one decision. It is four, and this page maps them.

About This Department

Across 202,934 women in the Netherlands with the same early-stage disease, the proportion who kept their breast ran from 58.5 percent in one region to 75.5 percent in another, and the gap survived every adjustment the researchers made for how sick the patients were. Same country, same guidelines, same decade. What differed was where the woman happened to be standing when she was diagnosed. Breast cancer surgery is not one decision, and this page is a map of the four that actually get made.

Free consultation

Ask which of the four decisions is still open in your case

Whether drug treatment comes first, whether the breast can be kept, how much of the armpit is operated on, and whether a reconstruction is part of the plan. Four separate questions. A single recommendation frequently answers all four at once without ever saying so, which is why a plan can feel impossible to argue with even when one of its four parts is genuinely open. Send the biopsy report with the receptor results, the grade and the HER2 status, the mammogram and ultrasound reports, the breast MRI if you have had one, the armpit ultrasound and any node biopsy, any genetic test result, and your medication list. A breast surgeon, a medical oncologist and a radiation oncologist review the file together and set out what each of the four decisions could reasonably be. No fee, no obligation, and a coordinator replies in your own language.

WhatsApp: +90 549 648 55 11 Send your file for a second opinion +90 549 648 55 11

Four decisions, in order

Almost every consultation ends with one sentence describing an operation. Underneath that sentence sit four separate questions, answered in this sequence, and each one has its own evidence and its own room for disagreement.

First, does anything happen before the operation

Chemotherapy or hormone treatment given before surgery shrinks the tumor, which can change what operation is possible, and it also shows everybody how the cancer responds to those drugs. This decision comes first because it changes everything downstream, and once surgery has happened it cannot be revisited.

Second, does the breast stay or go

Conserving the breast means removing the cancer with a margin and then irradiating what remains. Removing it means a mastectomy, with or without a rebuild. Survival is equivalent for women who qualify for either, so this is a decision about your life and not a decision about your odds.

Third, how much of the armpit is touched

Nothing, a sentinel node biopsy taking one or two nodes, or a full clearance. This decision is made largely independently of the breast decision, it drives most of the long-term arm trouble, and it is the one patients are told least about.

Fourth, is anything rebuilt, and when

Only relevant if the breast is coming off. Reshaping during conservation, a reconstruction at the same operation, a reconstruction later, or nothing at all. This is the decision with the widest range of defensible answers and the one most often presented as though it has only one.

Who actually decides

Recommendations arrive from a surgeon, but they are usually assembled by a group, and knowing which parts of it are firm is worth more than a general second opinion.

The multidisciplinary meeting

Surgeon, medical oncologist, radiation oncologist, radiologist and pathologist look at your file together and agree a plan. Ask for the conclusion in writing. That document is what any second opinion anywhere will want to read first, and asking for it also tells you whether such a meeting happened at all.

Re-reading the biopsy slides changes the label more than it changes the plan

When 263 referred biopsies were re-examined by specialist breast pathologists, 35 percent came back with a different diagnosis, most often a different grade. Nothing benign was reclassified as invasive. Management actually changed in 3 patients out of 263, which is 1 percent, and the surgical plan changed in one. Expert review is worth having, and it is not usually where the surprise comes from.

Re-reading the images changes rather more

Among 176 lesions in patients who sought a second opinion on their imaging before any cancer diagnosis, the specialist read disagreed with the original in 47 percent. A quarter of the lesions originally called suspicious were downgraded to benign, avoiding a biopsy. Thirty-nine percent of the benign or probably benign ones were upgraded. Of the cancers eventually found, just over a third had been missed on the first reading.

And you decide the rest

Where the evidence says two options are equivalent, and it says that more often than most consultations admit, the choice is yours by right rather than by concession. A team presenting equivalent options as equivalent is doing its job. A team presenting one of them as the sensible choice is quietly making your decision for you.

How much time you have

Almost everybody diagnosed with breast cancer feels that every day counts, and almost everybody is told there is time to think without being told how much. There are numbers. Across 351,087 women in an American national database who went straight to surgery, each additional month of waiting before the operation was associated with worse overall survival at a hazard ratio of 1.104. That effect did not differ between tumor types, which is worth knowing because triple-negative disease is often treated as though it demands more haste than the data supports.

Months are the unit that matters here, and not days. A study of 116,050 older American women looked specifically at the trade between seeing more doctors and starting later. Seeing two, three or four consultants was associated with better outcomes when the delay stayed small, with the benefit of three visits sitting at a hazard ratio of 0.71. The protection reversed once the delay passed roughly 33 days for new-patient visits and roughly 29 days for a medical oncology appointment, so a second opinion pays for itself when it happens quickly and stops paying once arranging it takes six weeks. That is worth knowing when you are deciding whether or not to chase one, because the honest version of the advice is not that second opinions are good or bad but that a fast one is worth having while a slow one costs more than it returns.

Something similar happens after surgery. Among 24,843 Californian women, starting chemotherapy between 31 and 90 days after the operation made no measurable difference against starting within 31 days, while past 91 days overall survival was worse at a hazard ratio of 1.34, and in triple-negative disease worse still at 1.53. Put those three findings together and the practical instruction is clear enough. You have a few weeks to get a second opinion, read properly and decide, but you do not have three months, and the moment a delay starts being measured in months it stops being deliberation and starts being drift.

Drugs before or after

Giving chemotherapy before the operation instead of after it is the same treatment in a different order, and it buys three things.

A smaller operation, sometimes. A tumor that shrinks may become removable with the breast intact, or the armpit may clear enough to avoid a full dissection, and this is the reason patients are usually given even though it is the least interesting of the three.
Information nothing else provides. Treating the cancer while it is still in the body shows exactly how it responds to those drugs. Pooling 12 international trials and 11,955 women, patients whose cancer disappeared completely from breast and nodes had better event-free survival at a hazard ratio of 0.44 and better overall survival at 0.36. In triple-negative disease that overall survival hazard ratio was 0.16, and in HER2-positive hormone-receptor-negative disease treated with antibody therapy it was 0.08.
A basis for changing the plan afterwards. If the cancer does not disappear, additional treatment can be added after surgery on the strength of that, and nothing equivalent exists for a patient who had surgery first, because the tumor is gone before anybody sees what the drugs would have done to it.
One important caveat about that headline. The same pooled analysis could not establish complete response as a valid stand-in for survival at the level of whole trials, with a coefficient of determination of 0.03. Complete disappearance is an excellent sign for the individual woman in front of you. It is not proof that a drug producing more of them saves more lives.

Two practical points follow. A small metal clip must be placed inside the tumor before treatment starts, because a cancer that melts away leaves nothing for the surgeon to find. And in a review of 33,162 American patients treated this way, 7.9 percent were upstaged rather than downstaged, meaning the disease turned out to be more extensive than the scans had suggested. The order of treatment does not change what is there.

The armpit question

The armpit is where the lasting damage lives and where the technique has changed most, and one situation in it is genuinely difficult and deserves setting out, which is a woman whose nodes were involved at diagnosis and who then had chemotherapy before surgery.

Chemotherapy clears the nodes surprisingly often. In a trial of 663 women with confirmed involved nodes before treatment, 41.0 percent had no cancer left in the armpit afterwards, which opens the possibility of avoiding a full clearance in four women out of every ten.
But a plain sentinel node biopsy is unreliable in this setting. The same trial measured how often sampling the sentinel nodes missed disease that a full clearance then found, and the answer was 12.6 percent, above the 10 percent the trial had set in advance as acceptable. A separate European study of 1,737 women found 14.2 percent in the same situation, rising to 24.3 percent when only one node was retrieved.
Marking the involved node before treatment fixes most of it. A clip is placed in the node that was proven to contain cancer, and that specific node is retrieved at surgery alongside the sentinel nodes. In 208 patients, checking the clipped node alone missed disease 4.2 percent of the time, sampling sentinel nodes alone missed it 10.1 percent of the time, and doing both together brought it down to 1.4 percent.
The clipped node is often not one of the sentinel nodes. In that study it was missed by sentinel sampling in 23 percent of patients, including six women whose sentinel nodes were clear while the clipped node still contained cancer. This is the entire argument for the technique, and it is a fair question to ask by name.

If your nodes were positive at the start and chemotherapy is being given first, ask whether a clip was placed in the involved node at the time of the biopsy. Ask it early, because the moment for placing it passes quickly and cannot be recovered afterwards.

The tests that decide chemotherapy

Tumor tissue can be sent for a test that reads the activity of a panel of genes and estimates how much a given woman would gain from chemotherapy. These tests change whether you have chemotherapy. They do not change which operation you have, and confusing the two wastes a lot of anxiety.

The twenty-one gene score

One trial enrolled 10,273 women with hormone-positive, HER2-negative, node-negative disease. Sixty-nine percent fell into the middle range of the score, and those 6,711 women were randomly assigned to hormone treatment alone or hormone treatment plus chemotherapy, and hormone treatment alone proved non-inferior at a hazard ratio of 1.08 with a confidence interval of 0.94 to 1.24. At nine years, overall survival was 93.9 percent without chemotherapy and 93.8 percent with it. A benefit from chemotherapy did appear in women aged 50 or under with scores between 16 and 25, which is the one group in that trial for whom the answer went the other way and the reason age is asked about before the test is even ordered. A second trial of 5,083 women with one to three involved nodes found the same split by menopause, with no chemotherapy benefit after menopause at a hazard ratio of 1.02, and a clear benefit before it at 0.60.

The seventy gene signature

A European trial of 6,693 women asked a narrower question, which was what happens to women whose clinical picture looks high risk but whose gene signature looks low risk. Those women omitted chemotherapy, and their five year survival free of distant spread carried a confidence interval running from 92.5 to 96.2 percent, close enough to the chemotherapy group that the trial supported leaving it out. What both of these tests do, in plain terms, is spare a large number of women a treatment that would have done them no good. Neither one tells your surgeon anything about the operation.

Diagnosis to operating room

Six things happen between the biopsy result and the anesthetic, and knowing the sequence tells you where you currently are.

The tumor is characterized. Estrogen receptor, progesterone receptor, HER2 status, grade and the proportion of dividing cells. These five results decide which drugs are relevant, and until they exist nobody can plan anything. Ask for them written out rather than summarized.

The extent is measured. Mammogram and ultrasound always, an MRI sometimes, and an ultrasound of the armpit with a needle sample of anything suspicious. This is what decides whether the breast can be kept, so an incomplete assessment produces an unnecessarily large operation.

Genetic testing, where it applies. Young age, a family history, triple-negative disease or a male patient all trigger it. The result changes the conversation about the other breast and about the ovaries, and it arrives on its own timetable, so ask when it was sent and when it is due.

The multidisciplinary meeting. Everything above is put in front of the whole team and a plan is agreed. This is the moment the four decisions get made, usually without you in the room, which is exactly why the written conclusion matters.

The conversation where you decide. The plan is presented and, where options are equivalent, your preference settles it. Bring somebody with you and bring written questions, because almost nobody retains a consultation like this unaided.

Preparation, and anything time-sensitive. Fitness for anesthetic, and for a younger woman a fertility discussion that has to happen before any chemotherapy rather than after it. Everything in this step has a deadline that quietly passes if nobody raises it.

The operations themselves

Five operations cover almost everything done for breast cancer and each is a full subject in its own right, so the table gives you enough to know which one is being proposed and what its central trade is.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

The five operations, what each one is for, and the trade it makes
Operation	Who it is for	The trade
Lumpectomy, also called breast-conserving surgery	Most women with a single tumor of modest size relative to the breast.	You keep the breast and accept radiotherapy afterwards, plus a lifetime of surveillance on the tissue that stays.
Oncoplastic conservation	A tumor too large for a plain lumpectomy, an awkward position, or larger breasts that would benefit from being reshaped and reduced at the same time.	More tissue can be removed and cleanly, at the cost of a bigger operation, more scars and a modestly higher complication rate.
Mastectomy without reconstruction	Extensive disease, radiotherapy that cannot be given, or simply a woman who would rather not keep the breast.	The shortest recovery and nothing foreign in the body. Against that, a permanently changed chest.
Mastectomy with reconstruction	The same indications, where the woman wants a breast shape rebuilt.	A breast shape, against a much longer operation, more complications, and often more than one procedure.
Armpit surgery, added to any of the above	A sentinel node biopsy for most, a full clearance where nodes are known to be involved, and increasingly nothing at all in selected patients.	Staging information and local control, against arm swelling, numbness and stiffness that can be permanent.

Whichever appears on your consent form, ask which of the four decisions it is answering and whether the others were considered separately, because a single recommendation frequently bundles all four together and the bundle is much harder to argue with than its parts.

When surgery is not the plan

Not every breast cancer is operated on, and two situations account for most of the exceptions.

Hormone tablets instead of an operation

For an older woman with a hormone-sensitive cancer, tablets alone can control the disease for years. A Cochrane review pooled seven randomized trials covering roughly 1,571 women aged 70 and over. Overall survival did not differ significantly between surgery and tablets alone, at a hazard ratio of 0.98 for surgery alone and 0.86 for surgery combined with tablets. What did differ was control of the cancer where it sat, with surgery clearly better on progression-free survival at hazard ratios of 0.55 and 0.65. Those reviewers concluded that tablets alone should be reserved for women who are unfit for surgery or who decline it, which remains the mainstream position, and the trials all used tamoxifen rather than the modern drugs. It is a real option for a frail patient and a poor one for a fit patient of any age. Where it is chosen, the tablets have to be taken and the breast has to be examined and scanned on a schedule, because a cancer controlled by tablets is being managed rather than removed and it can start growing again years later.

Surgery deferred while drugs work

Deferring surgery is temporary by design. Where chemotherapy or hormone treatment is given first, the operation waits several months, which frightens patients who have been told that speed matters, and the answer is that the wait is planned rather than accidental, the cancer is under treatment throughout, and the response is monitored with scans. What matters is that the surgery happens at the end of it. Somebody has to have the date written down.

Why the stage keeps changing

Patients are given a stage at diagnosis, told a plan built on it, and then given a different stage after the operation. This is not somebody having been wrong. The stage before surgery is an estimate assembled from images, and the stage after surgery is a measurement made under a microscope, and they disagree far more often than anybody says out loud.

In 307 consecutive patients going straight to surgery, the stage before and after disagreed in 48.5 percent, upward in 22.1 percent and downward in 26.4 percent. The nodes were the worst of it. Just over half the women whose armpits looked clear turned out to have involved nodes, while just over a quarter of those thought to have involved nodes had none.

That is a single center and the numbers elsewhere will differ, but the direction is universal and the lesson is practical, so expect the plan to be revised once the pathology arrives and do not treat the first version of it as a promise. It also explains why the pathology report is the most important document you will be given, and why taking it home in your hand rather than as a summary is worth insisting on.

What to do beforehand

Five things are worth doing in the weeks before surgery, and one of them has a deadline that cannot be moved.

If you might want children, raise it now. Chemotherapy can end fertility and the preservation has to happen before it starts. A review of 22 studies found that starting ovarian stimulation at any point in the cycle produced a comparable number of eggs to waiting for the conventional starting point, so the old reason for delay has gone. Two cycles yielded 7.91 more eggs on average than one, and adding letrozole kept estrogen levels significantly lower during the process. Ask for a fertility referral in the same conversation where chemotherapy is first mentioned.

Understand what your weight does to the odds. Pooling 29 studies and 71,368 patients having breast reconstruction, a body mass index above 30 carried a risk ratio of 2.29 for surgical complications, 2.89 for medical ones and 1.91 for needing another operation. That evidence is specific to reconstruction and it should inform the choice of operation rather than disqualify anybody from having one.

Stop smoking, and say that you have. Nicotine constricts the small vessels that keep skin flaps alive, which is the mechanism behind most wound healing problems in breast surgery. The evidence specific to breast operations is thinner than the general surgical evidence, so treat this as a strong recommendation rather than a quantified one.

Get the paperwork in one place. The biopsy report with receptors and grade, the imaging reports with measurements, the multidisciplinary meeting conclusion, the genetic result, your medication list. Every second opinion, at home or abroad, starts by asking for exactly these, and assembling them once saves a fortnight later.

Ask about enhanced recovery. Structured protocols covering fasting, pain relief without heavy opioids and early mobilization shortened hospital stays by a mean of 1.57 days across 16 studies of flap reconstruction, with no increase in flap loss, reoperation, readmission or infection. Not every unit runs one. Asking tells you something about the unit either way.

Deciding well

How people decide about treatment has a research literature of its own, and it is more encouraging than most people expect. Structured decision aids have been tested in randomized trials repeatedly, meaning a booklet or a tool that lays out the options with their numbers attached and then asks you what matters most to you. A living Cochrane review has now assembled 209 of those trials covering 107,698 people, with breast cancer among the best represented decisions in it.

People given a decision aid were 75 percent more likely to end up with the choice that actually matched their own values, scored nearly 12 points higher out of 100 on knowledge, and were substantially less likely to leave the decision to the clinician. Regret afterwards did not differ.

Two findings there are worth pulling out separately. Accurate understanding of risk improved at a risk ratio of 1.94, meaning people who used one were nearly twice as likely to hold a realistic picture of what would happen to them. And using an aid before the consultation did not lengthen it, while using one during the consultation added about a minute and a half. So the objection that this takes time is not supported. Ask whether your unit has one for the decision you are facing, and if it does not, the effect of writing your questions down beforehand and bringing somebody to take notes points in the same direction.

The pathology report

Everything after surgery is built from this document, and most patients are given a verbal summary of it and never see the thing itself. Each line changes something specific.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

What each line of the report after surgery decides
The line	What it says	What it changes
Tumor size and type	The measurement under the microscope, often different from the scan.	Stage, and with it the case for chemotherapy and for radiotherapy after a mastectomy.
Grade	How abnormal the cells look, from one to three.	The estimate of how the cancer behaves, and whether a gene test is worth doing.
Margin status	Whether cancer reaches the edge of what was removed, and by how much.	Whether you go back to the operating room, and this is the line most likely to change the plan you agreed.
Nodes removed and nodes involved	Two numbers, and both matter, because three out of fifteen is a different situation from three out of three.	Chemotherapy, radiotherapy to the nodes, and whether more armpit surgery is discussed.
Receptors and HER2	Confirmed on the whole tumor rather than on the small biopsy sample.	Every drug decision for the next five to ten years. Occasionally different from the biopsy result.
Lymphovascular invasion	Whether cancer is seen inside small vessels around the tumor.	Shifts the balance toward chemotherapy and toward treating the nodes.
Response, where drugs came first	Whether cancer remains in the breast, the nodes, both or neither.	Prognosis, and whether additional treatment is added after surgery on the strength of residual disease.

Recovery and flying home

Recovery depends far more on which operation you had than on the cancer itself, and the range is wide.

Hospital. A lumpectomy is often a day case. A mastectomy is a night, sometimes none. An implant reconstruction is one or two nights, and a reconstruction using your own tissue is four to six because the blood supply is watched closely.
Drains. Used after a mastectomy and after armpit clearance, rarely after a lumpectomy. They stay from several days to a fortnight, and you will be taught to empty and record them before you leave.
Your shoulder. Exercises start within a day or two whenever the armpit has been operated on, and they are not optional. A shoulder protected for a fortnight stiffens and takes months to free.
Flying. Roughly five to seven days after a lumpectomy, seven to ten after a mastectomy or an implant reconstruction, and two to three weeks after tissue transfer. Later in every case if a drain is still in place.
The pathology report. About a week. Waiting for it is usually the reason a stay is longer than the operation alone would need, and carrying it home in your hand is worth the wait.
Once you are back home. A wound check within a fortnight, an oncology appointment booked before you fly, and a surveillance plan in writing, because the gap between surgery and the rest of the treatment is where cross-border care most often goes wrong.

Why answers differ

Surgeons looking at the same file frequently propose different operations, and patients understandably read that as one of them being wrong. Usually neither is. Dutch researchers followed 202,934 women through their national registry, with early breast cancer across nine regions over 26 years, and in the earlier period the proportion keeping the breast ranged from 39.0 percent to 71.7 percent depending on which region a woman lived in. Practice improved everywhere over time, and by the later period the national average had risen to 67.4 percent, but the spread between regions was still 58.5 to 75.5 percent. Adjusting for how sick the patients were did not remove it.

What that measures is not competence. It is the accumulated effect of what each unit is equipped to do, what its surgeons were trained to do, how it presents choices and what its patients have come to expect. A hospital without an oncoplastic surgeon will honestly describe fewer conservation options, and a hospital without a microsurgical team will honestly describe fewer reconstruction options, and in neither case will anybody say so out loud, because from inside the unit the recommendation looks like the medicine and not like the menu, which is the ordinary way this happens rather than anybody being dishonest with you. This is the strongest single argument for a second opinion, and it is also why the question worth asking is not whether the recommendation is right but what else was considered and why it was set aside. That question is answerable, it is not rude, and the quality of the answer tells you a great deal about the unit giving it.

Questions to ask

Start by separating the four decisions. Ask whether drug treatment before surgery was considered and why it was or was not chosen, then ask whether the breast could be kept and what specifically rules it out if the answer is no, then ask exactly what is planned for the armpit, and only then ask about reconstruction. A recommendation that answers all four at once is much harder to examine than four answers given separately.

Then ask for the multidisciplinary meeting conclusion in writing, which tells you both what was agreed and whether the meeting happened. Ask what would change if you took four weeks to decide, since the evidence puts the risk of a month at a hazard ratio close to 1.1 and the risk of three months a great deal higher. If chemotherapy is being given first and your nodes were involved, ask whether a clip has been placed in the involved node, and if you might want children, ask for a fertility referral in that same conversation. And finally, ask what else was considered and set aside, because the regional variation data says the answer to that question is where the real information lives. Write these down before the appointment and bring somebody with you to take notes, since almost nobody retains a consultation like this on their own, and the parts people forget are reliably the parts that mattered.

Reading a quote

No figure appears on this page, and breast cancer treatment is a sequence rather than a single event, so a number quoted for the operation alone is answering a smaller question than the one you are asking. Six things belong in writing. Which operation the quote covers, since a lumpectomy and a mastectomy with a microsurgical reconstruction sit at opposite ends of any price list, and whether the armpit procedure is inside or added, given that no armpit surgery, a sentinel node biopsy and a full clearance are three different operations. Whether the pathology examination of everything removed is included, which is the document the rest of your treatment depends on. Whether a second operation for margins is charged again and at what proportion. Whether radiotherapy and drug treatment are inside the quote, alongside it, or expected to happen at home, and how many nights are budgeted, given the difference between a day case and a six night stay after tissue transfer.

Your own file moves the total more here than in almost any other specialty. Which operation, whether the armpit is cleared, whether a reconstruction is part of it and whether drug treatment comes first are the four variables that decide the number.

Packages published by Turkish hospitals and medical travel agencies for breast cancer surgery generally include the airport transfer, pre-operative testing, the surgeon and anesthesia fees, the operating room, the planned nights, the pathology, an interpreter and the review before departure. They generally exclude flights, insurance, radiotherapy, drug treatment, gene expression testing, a second operation, treatment of a complication and hotel stays past an agreed number. Read what arrives against both lists.

Coming to Istanbul

Ten to fourteen days covers assessment, an operation and the pathology report for somebody arriving with the diagnostic work already complete, and around three weeks where a reconstruction uses tissue taken from your own body. Where drug treatment is being given before surgery, the shape of the trip changes completely and is worth settling in the first conversation, since many patients have that treatment at home and travel only for the operation. Send the biopsy report before anything else, with the receptor status, the HER2 result, the grade and the proportion of dividing cells written out. A report saying only that cancer was found cannot be turned into a plan. Add the mammogram and ultrasound reports with the measurements, any breast MRI, the armpit ultrasound and any node biopsy, the genetic test result if you have one, the multidisciplinary meeting conclusion from home if there was one, and your medication list.

Say in your first message which of the four decisions you feel least settled about, because that is where the review should spend its time, and somebody who has accepted a mastectomy but wants to understand reconstruction needs a different consultation from somebody who has not accepted the mastectomy at all. Only one coordinator holds your file from the first message to discharge, and the international patients team works in English, Arabic, French, Russian, Serbian, Romanian and Spanish, with other languages arranged on request. Ask in your first message if you would prefer a female physician. Someone can stay overnight with you on the ward, where the rooms carry a companion bed. Meals from the hospital kitchen cover halal, vegetarian and diabetic diets and a prayer room is available. The international patients office books accommodation for both of you, arranges the airport transfer and daily transport, and prepares the appointment confirmation and the invitation letter naming the hospital and your treating doctor for a medical visa application, around ten days before travel.

Take home the pathology report itself and not a summary, with the tumor size and type, the grade, the margin status in millimeters, the number of nodes removed and the number involved, and the full receptor and HER2 results. Take the operation note, which should name the operation performed and what was done to the armpit, and take the multidisciplinary meeting conclusion with its recommendation about radiotherapy and drug treatment. Address the file to a breast oncologist near you and book that appointment before you fly, because the interval between surgery and the rest of the treatment is the part of the pathway that fails when two health systems are involved. Once you are back home, your coordinator stays reachable on the same WhatsApp number, so a question about a wound or a line in the report reaches somebody with your notes in front of them.

Breast cancer surgery FAQ

How long can I safely wait before surgery?

Weeks rather than months. Across 351,087 patients, each additional month before surgery carried a hazard ratio of 1.104 for overall survival, and the effect did not differ by tumor type. Getting a second opinion is worth it if it happens quickly, and the benefit reverses once the extra delay passes roughly a month.

Is it worth getting a second opinion on my scans and slides?

More so on the scans. Specialist re-reading of imaging disagreed with the original in 47 percent of 176 lesions and just over a third of the cancers found had been missed first time. Expert re-reading of biopsy slides changed the diagnosis in 35 percent of 263 cases but changed management in only 1 percent.

Why would chemotherapy be given before surgery?

For a smaller operation and for information. Pooling 12 trials and 11,955 women, those whose cancer disappeared completely had better overall survival at a hazard ratio of 0.36, and 0.16 in triple-negative disease. Insist that a clip is placed in the tumor before treatment starts.

My nodes were positive and I am having chemotherapy first. What happens to my armpit?

Chemotherapy cleared the nodes in 41.0 percent of one trial's patients. Plain sentinel node sampling missed disease 12.6 percent of the time in that setting. Marking the involved node with a clip and retrieving it alongside the sentinel nodes brought the miss rate down to 1.4 percent.

Will a gene test change my operation?

No. It changes whether you have chemotherapy. In a trial of 10,273 women, 69 percent had a mid-range score and those randomized to hormone treatment alone did as well as those given chemotherapy too, with nine year overall survival of 93.9 against 93.8 percent.

Why did my stage change after the operation?

Because the first one was an estimate from images. In 307 consecutive patients, the stage before and after surgery disagreed in 48.5 percent, and just over half of those whose armpits looked clear turned out to have involved nodes. Expect the plan to be revised once the pathology arrives.

I want children later. When do I raise that?

In the same conversation where chemotherapy is first mentioned, because preservation has to happen before treatment starts. Stimulation can now begin at any point in the cycle with a comparable number of eggs retrieved, so the old reason for delaying no longer applies.

Can an older woman avoid surgery and take tablets instead?

Sometimes. Pooling seven trials in women over 70, overall survival did not differ significantly between surgery and tamoxifen alone, but control of the cancer locally was clearly better with surgery, at hazard ratios of 0.55 and 0.65. The reviewers reserved tablets alone for women unfit for or declining surgery.

Two surgeons have told me different things. Which one is right?

Often both. Across 202,934 Dutch women, the proportion keeping the breast ranged from 58.5 to 75.5 percent between regions and the gap survived adjustment for how sick the patients were. Ask each surgeon what else was considered and why it was set aside.

How long should I stay in Turkey?

Ten to fourteen days for a lumpectomy or a mastectomy with or without an implant, and around three weeks where tissue is transferred from the abdomen. Flying is cleared at five to seven days in the simplest case and at two to three weeks in the most complex of them.

References

Mateo AM, Mazor AM, Obeid E, Daly JM, Sigurdson ER, Handorf EA, DeMora L, Aggon AA, Bleicher RJ. Time to surgery and the impact of delay in the non-neoadjuvant setting on triple-negative breast cancers and other phenotypes. Annals of Surgical Oncology. 2020;27(5):1679-1692.
Egleston BL, Bleicher RJ, Fang CY, Galloway TJ, Vucetic S. Benefits versus drawbacks of delaying surgery due to additional consultations in older patients with breast cancer. Cancer Reports. 2023;6(5):e1805.
Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncology. 2016;2(3):322-329.
Woeste MR, Jacob K, Duff MB, Donaldson M, Sanders MAG, McMasters KM, Ajkay N. Impact of routine expert breast pathology consultation and factors predicting discordant diagnosis. Surgical Oncology. 2022;45:101860.
Coffey K, Mango V, Keating DM, Morris EA, D'Alessio D. The impact of patient-initiated subspecialty review of breast imaging on subsequent patient care. Journal of the American College of Radiology. 2018;15(8):1109-1115.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. The New England Journal of Medicine. 2018;379(2):111-121.
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. The New England Journal of Medicine. 2021;385(25):2336-2347.
Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. 70-gene signature to aid treatment decisions in early-stage breast cancer. The New England Journal of Medicine. 2016;375(8):717-729.
Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Tamirisa N, Force J, Boughey JC, Hyslop T, Hwang ES. The clinical significance of breast-only and node-only pathologic complete response after neoadjuvant chemotherapy, a review of 20,000 breast cancer patients in the National Cancer Data Base. Annals of Surgery. 2018;268(4):591-601.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer, the CTNeoBC pooled analysis. The Lancet. 2014;384(9938):164-172.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer, the ACOSOG Z1071 clinical trial. JAMA. 2013;310(14):1455-1461.
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA), a prospective, multicenter cohort study. The Lancet Oncology. 2013;14(7):609-618.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes, implementation of targeted axillary dissection. Journal of Clinical Oncology. 2016;34(10):1072-1078.
Chen CN, Chang LT, Chen CH, Tam KW. Fertility preservation for women with breast cancer before chemotherapy, a systematic review and meta-analysis. Reproductive BioMedicine Online. 2022;44(2):357-369.
Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women, 70 years plus. Cochrane Database of Systematic Reviews. 2006;1(1):CD004272.
Tan YY, Liaw F, Warner R, Myers S, Ghanem A. Enhanced recovery pathways for flap-based reconstruction, systematic review and meta-analysis. Aesthetic Plastic Surgery. 2021;45(5):2096-2115.
Stacey D, Lewis KB, Smith M, Carley M, Volk R, Douglas EE, Pacheco-Brousseau L, Finderup J, Gunderson J, Barry MJ, Bennett CL, Bravo P, Steffensen K, Gogovor A, Graham ID, Kelly SE, Legare F, Sondergaard H, Thomson R, Trenaman L, Trevena L. Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews. 2024;1(1):CD001431.
van Maaren MC, Strobbe LJA, Koppert LB, Poortmans PMP, Siesling S. Nationwide population-based study of trends and regional variation in breast-conserving treatment for breast cancer. British Journal of Surgery. 2018;105(13):1768-1777.
Panayi AC, Agha RA, Sieber BA, Orgill DP. Impact of obesity on outcomes in breast reconstruction, a systematic review and meta-analysis. Journal of Reconstructive Microsurgery. 2018;34(5):363-375.
Goyal S, Jacob LA, Lokanatha D, Suresh Babu MC, Lokesh KN, Rudresha AH, Saldanha S, Amirtham U, Thottian AGF, Rajeev LK. Discordance in clinical versus pathological staging in breast cancer, are we undermining the significance of accurate preoperative staging in the present era? Breast Disease. 2022;41(1):115-121.

Editor's note

Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Halil ERBİS, General Surgery.

Medically reviewed by

Prof. Dr. Halil ERBİS

General Surgery

Related Treatments

View All